Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: The FAVORIT trial

American Journal of Transplantation

Volumn 12, Issue 9, 2012, Pages 2437-2445

  Weiner, D E ^a   Carpenter, M A ^b   Levey, A S ^a   Ivanova, A ^b   Cole, E H ^c   Hunsicker, L ^d   Kasiske, B L ^e   Kim, S J ^c   Kusek, J W ^f   Bostom, A G ^g  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF IOWA   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g RHODE ISLAND HOSPITAL   (United States)

Author keywords

Cardiovascular disease; chronic kidney disease; epidemiology; glomerular filtration rate; kidney transplant; mortality

Indexed keywords

CREATININE; CYANOCOBALAMIN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; PYRIDOXINE; TRIACYLGLYCEROL;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84865587570     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04101.x     Document Type: Article

References (36)

1. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, et al,. US Renal Data System 2010 Annual Data Report. Am J Kidney Dis 2011; 57: A8, e1-526.
2. Kasiske BL, Chakkera HA, Roel J,. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735-1743.
3. Israni AK, Snyder JJ, Skeans MA, Peng Y, Maclean JR, Weinhandl ED, et al,. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant 2010; 10: 338-353.
4. Meier-Kriesche HU, Baliga R, Kaplan B,. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291-1295. (Pubitemid 36513036)
5. Kasiske BL, Israni AK, Snyder JJ, Skeans MA,. The relationship between kidney function and long-term graft survival after kidney transplant. Am J Kidney Dis 2011; 57: 466-475.
6. Vanrenterghem YF, Claes K, Montagnino G, Fieuws S, Maes B, Villa M, et al,. Risk factors for cardiovascular events after successful renal transplantation. Transplantation 2008; 85: 209-216. (Pubitemid 351222383)
7. Jardine AG, Fellstrom B, Logan JO, Cole E, Nyberg G, Gronhagen-Riska C, et al,. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis 2005; 46: 529-536. (Pubitemid 41208190)
8. Soveri I, Holdaas H, Jardine A, Gimpelewicz C, Staffler B, Fellstrom B,. Renal transplant dysfunction-importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Nephrol Dial Transplant 2006; 21: 2282-2289. (Pubitemid 44295057)
9. Bostom AG, Carpenter MA, Hunsicker L, Jacques PF, Kusek JW, Levey AS, et al,. Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. Am J Kidney Dis 2009; 53: 121-128.
10. Bostom AG, Carpenter MA, Kusek JW, Hunsicker LG, Pfeffer MA, Levey AS, et al,. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial. Am Heart J 2006; 152: 448 e1-7.
11. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al,. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
12. 2. Am J Kidney Dis 2010; 56: 486-495.
13. Chikkalingaiah KB, Grant ND, Mangold TM, Cooke CR, Wall BM,. Performance of simplified modification of diet in renal disease and Cockcroft-Gault equations in patients with chronic spinal cord injury and chronic kidney disease. Am J Med Sci 2010; 339: 108-116.
14. Oterdoom LH, Gansevoort RT, Schouten JP, de Jong PE, Gans RO, Bakker SJ,. Urinary creatinine excretion, an indirect measure of muscle mass, is an independent predictor of cardiovascular disease and mortality in the general population. Atherosclerosis 2009; 207: 534-540.
15. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL,. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006; 114: 1572-1580. (Pubitemid 44547427)
16. Friedewald WT, Levy RI, Fredrickson DS,. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
17. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY,. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
18. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al,. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-2081.
19. Weiner DE, Tabatabai S, Tighiouart H, Elsayed E, Bansal N, Griffith J, et al,. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis 2006; 48: 392-401. (Pubitemid 44247251)
20. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al,. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15: 1307-1315. (Pubitemid 38526012)
21. Baber U, de Lemos JA, Khera A, McGuire DK, Omland T, Toto RD, et al,. Nontraditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort. Kidney Int 2008; 73: 615-621. (Pubitemid 351264109)
22. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, et al,. The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am J Kidney Dis 2008; 51: 212-223.
23. Pilmore HL, Skeans MA, Snyder JJ, Israni AK, Kasiske BL,. Cardiovascular disease medications after renal transplantation: results from the patient outcomes in renal transplantation study. Transplantation 2011; 91: 542-551.
24. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S261-S266.
25. KDIGO Guideline for CKD Classification and Management. Guideline 1. Definition and Stages of Chronic Kidney Disease. [cited 2011 March 16]; Available from: http://www.kdigo.org/clinical-practice-guidelines/CKD.php
26. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9: S151-S155.
27. Eckardt KU, Berns JS, Rocco MV, Kasiske BL,. Definition and classification of CKD: The debate should be about patient prognosis-a position statement from KDOQI and KDIGO. Am J Kidney Dis 2009; 53: 915-920.
28. Fellstrom B, Jardine AG, Soveri I, Cole E, Neumayer HH, Maes B, et al,. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant 2005; 5: 1986-1991. (Pubitemid 41039875)
29. Kukla A, Adulla M, Pascual J, Samaniego M, Nanovic L, Becker BN, et al,. CKD stage-to-stage progression in native and transplant kidney disease. Nephrol Dial Transplant 2008; 23: 693-700. (Pubitemid 351767613)
30. Kasiske BL, Israni AK, Snyder JJ, Camarena A, COST Investigators. Design Considerations and Feasibility for a Clinical Trial to Examine Coronary Screening Before Kidney Transplantation (COST). Am J Kidney Dis 2011; 57: 908-916.
31. Lentine KL, Hurst FP, Jindal RM, Villines TC, Kunz JS, Yuan CM, et al,. Cardiovascular risk assessment among potential kidney transplant candidates: approaches and controversies. Am J Kidney Dis 2010; 55: 152-167.
32. Aguilar MI, O'Meara ES, Seliger S, Longstreth WT, Jr,., Hart RG, Pergola PE, et al,. Albuminuria and the risk of incident stroke and stroke types in older adults. Neurology 2010; 75: 1343-1350.
33. DeFilippis AP, Kramer HJ, Katz R, Wong ND, Bertoni AG, Carr J, et al,. Association between coronary artery calcification progression and microalbuminuria: the MESA study. JACC Cardiovasc Imaging 2010; 3: 595-604.
34. O'Seaghdha CM, Hwang SJ, Upadhyay A, Meigs JB, Fox CS,. Predictors of incident albuminuria in the Framingham Offspring cohort. Am J Kidney Dis 2010; 56: 852-860.
35. Warnock DG, Muntner P, McCullough PA, Zhang X, McClure LA, Zakai N, et al,. Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study. Am J Kidney Dis 2010; 56: 861-871.
36. Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, et al,. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the folic Acid for vascular outcome reduction in transplantation trial. Circulation 2011; 123: 1763-1770.